The Limited Times

Now you can see non-English news...

Vaccines: Astra Zeneca sales reach more than $ 1 billion in the first half of 2021

2021-07-29T08:05:49.324Z


The Swedish-British pharmaceutical group has suffered greatly from delays in deliveries and then from the appearance of serious side effects.


Pharmaceutical company AstraZeneca announced Thursday that sales of its Covid-19 vaccine reached $ 1.17 billion in the first half of the year. This figure corresponds to the delivery of approximately 319 million doses worldwide. Sales represented $ 572 million in Europe, and $ 455 million in emerging countries, where the group is extremely present thanks to the Covax program. The company's turnover nonetheless grew 23% year-on-year to reach $ 15.5 billion and net profit by 40%. It now stands at 2.1 billion.

The group welcomes in a statement the progress in its product portfolio with the recent acquisition of the American biotech Alexion, specializing in rare diseases.

For CEO Pascal Soriot, “AstraZeneca generated a new period of strong growth thanks to solid performance in all regions and in all pathologies”, particularly in oncology.

Pfizer in another sphere

However, a time neck and neck with the American Pfizer, Astrazeneca is no longer boxing in the same category as the number one anti-Covid vaccine.

The Swedish-British company paid for its exclusion from the market for long weeks, in France in particular, after the announcement of rare cases of thrombosis in some vaccinated people.

Since then, AstraZeneca is no longer administered to persons under the age of 55 in France, thus abandoning a significant market share for RNA vaccines Messager Moderna and Pfizer.

Despite the support of the WHO, for which the risk-benefit balance is positive, Astrazeneca's image has been negatively impacted by these controversies.

Read also Anti-Covid vaccination: how AstraZeneca fell from 50% to less than 1% of daily first injections

It is therefore no surprise that Pfizer's vaccine sales figures and forecasts have nothing to do with those of AstraZeneca. The American company plans to sell this year for 33.5 billion dollars of vaccines developed with the German BioNTech. The objectives have been revised upwards, while sales of anti-Covid vaccines have already brought him $ 11.3 billion in the first six months of 2021. And this figure should swell with the imminent demand for authorization for a third dose of its vaccine in the United States and Europe.

Source: leparis

All business articles on 2021-07-29

You may like

Life/Entertain 2024-02-24T12:52:00.629Z

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.